The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. METHODS: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. RESULTS: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I(2) = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I(2) = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. CONCLUSIONS: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants have small, statistically significant positive effects on psychomotor speed and delayed recall in major depressive disorder, but not on cognitive control or executive function. Head-to-head trials showed no statistically significant differences between antidepressant classes, and the psychomotor speed effect lost significance after removing vortioxetine.
Key findings
- In nine placebo-controlled randomized trials (2,550 participants), antidepressants improved psychomotor speed (SMD 0.16; 95% CI 0.05–0.27; I² = 46%) and delayed recall (SMD 0.24; 95% CI 0.15–0.34; I² = 0%). Effects on cognitive control (SMD 0.10; 95% CI −0.06 to 0.26; p = 0.21) and executive function (SMD 0.12; 95% CI −0.03 to 0.28; p = 0.12) were not statistically significant.
- Vortioxetine had the largest pooled effect size (0.34; 95% CI 0.17–0.50; p = 0.0001), followed by duloxetine (0.10; 95% CI −0.01 to 0.22). After removing vortioxetine, the psychomotor speed effect was no longer significant (SMD 0.08; 95% CI −0.02 to 0.18; p = 0.13).
- In head-to-head trials, no statistically significant difference was found between SSRIs/SNRIs and TCAs on pooled memory domains (SMD 0.33; 95% CI −0.11 to 0.78; p = 0.14), or between SSRIs and NDRIs on working memory (SMD −0.22; 95% CI −0.62 to 0.19). Sertraline outperformed fluoxetine on psychomotor speed (SMD 0.38; 95% CI 0.11–0.66; p = 0.006).
- A subgroup analysis found a greater positive effect in subjects younger than 65 (SMD 0.23; 95% CI 0.04–0.43; p = 0.02) than in those older than 65 (SMD 0.10; 95% CI 0.00–0.21; p = 0.06), but the difference between subgroups was not statistically significant (p = 0.24).
Methods
- Systematic review and meta-analysis of randomized clinical trials published before April 15, 2015, identified through Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Inclusion required adults over 18 with MDD, antidepressant monotherapy with monoamine modulation, and cognition assessed by standardized validated measures.
- Data were pooled using standard mean differences (SMD) with a random-effects model in Review Manager 5.3. Placebo-controlled trials compared final cognitive scores of antidepressant versus placebo; head-to-head trials compared one antidepressant with another. Risk of bias was assessed across five domains, and a funnel plot was created for psychomotor speed.
- Searches yielded 1,084 articles plus 23 from reference lists; 45 full texts were reviewed, 25 studies were included qualitatively, and 17 were included quantitatively. Nine placebo-controlled trials and eight head-to-head trials contributed to the meta-analysis.
Limitations
- The paper states that high heterogeneity of cognitive testing limited comparison and pooling, that moderate heterogeneity was present in pooled SMDs, that the number of studies and sample sizes were small, and that vortioxetine and duloxetine were heavily weighted; removing vortioxetine eliminated statistical significance for psychomotor speed.
- The paper also states that many included studies had potential for-profit bias due to pharmaceutical company funding, and that the functional meaning of the small cognitive test improvements remains largely unknown.
- Evident from the text: an Egger test could not be performed because fewer than ten studies were available, funnel plot interpretation was limited, most studies evaluated cognition as a secondary outcome, and responder/non-responder subgroup analyses were not possible due to insufficient reporting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









![Figure 10. Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.](https://figures.cochat.ai/paper-figures/30fee3d872fd45778bc9237ce37a68a7/the-cognitive-effects-of-antidepressants-in-major-depressive-disorder-a-figure-10.jpg)
Verification
Claims the paper makes
5 Valid · 2 Not valid · 3 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several cognitive domains, including executive function, attention, memory, processing speed, and psychomotor skills, are affected during both symptomatic as well as “remitted” phases in MDD (Marazziti et al., 2010; Lee et al., 2012; Bora et al., 2013; Bortolato et al., 2014).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Marazziti et al., 2010 source
- Not checked — no full text of the sourcecites Lee et al., 2012 source
- Partly supportedcites Bora et al., 2013 sourceExperimental — accuracy not yet measured
The Cognitive domains results (page not provided) report poorer performance in euthymic MDD patients across the domains studied, including executive function, attention, memory, and processing speed. The Introduction says cognitive functions are often impaired in MDD, but this meta-analysis does not establish that every listed domain is affected during symptomatic phases; the Discussion addresses psychomotor inhibitory control specifically, not psychomotor skills broadly. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, since the publication of their review, several new clinical trials have been published that have primarily sought to determine the effects of antidepressants on cognitive function (Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Soczynska et al., 2014; Gorlyn et al., 2015; Mahableshwarkar et al., 2015).”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Introduction
What the sources say
- Not checked — no full text of the sourcecites Katona et al., 2012 source
- Supportedcites McIntyre et al., 2014 source
The Discussion identifies this as a large randomized study in adults with major depressive disorder whose pre-defined primary clinical outcome was cognitive performance. It therefore supports citing McIntyre et al. (2014) as one of the trials primarily designed to test an antidepressant’s effects on cognition. (LLM, conf=0.94)
- Not matchedcites Robinson et al., 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pooled effect size of both antidepressants (n = 989) versus placebo (n = 616) was 0.24 (95% CI 0.15 to 0.34; p < 0.00001), indicative of a small, yet statistically significant, positive effect”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedstates a causen = 989 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The SMD of all antidepressants (n = 984) versus placebo (n = 494) was 0.12 (95% CI -0.03 to 0.28; p = 0.12) is shown in Figure 6, indicative of a non–statistically significant effect.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
hedgedn = 984- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Abstract > Results:
plainn = 2,550- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 46 claims and every source verdict.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 5
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, a significant proportion of MDD patients continue to experience significant cognitive impairment.”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis further indicates that standard antidepressant drugs may ameliorate certain cognitive domains in patients with MDD, namely psychomotor speed and delayed recall [20].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
In the citing paper
“Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has been demonstrated to have procognitive effects compared to placebo.65”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [65]
In the citing paper
“However, the evidence base remains limited, and the effect sizes derived from this meta-analysis were small in magnitude (standard mean difference was 0.16 for psychomotor speed and 0.24 for delayed recall, respectively).”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Search Results and Study Characteristics
“Of the articles included in the quantitative review, nine were placebo-controlled randomized trials, with four trials evaluating two antidepressants compared to the same placebo group and the remaining evaluating a single antidepressant compared to placebo.”
§ The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials > Results > Pooled Effect Sizes for Placebo-Controlled Trials
“In total, nine placebo-controlled studies evaluated psychomotor speed using DSST or a combined speed measure (Georgotas et al., 1989; Ferguson et al., 2003; Raskin et al., 2007; Hoffman et al., 2008; Culang et al., 2009; Katona et al., 2012; McIntyre et al., 2014; Robinson et al., 2014; Mahableshwarkar et al., 2015). Of these studies, three studies evaluated two agents in parallel compared to placebo”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
A compendium of neuropsychological tests: administration, norms, and commentary
(1991) · Choice Reviews Online · doi:10.5860/choice.29-2400 · Cited by 6,120
Strauss, E., & Spreen, O. (2009) · Cited by 1,444
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868 · cited 1×
“2 | International Journal of Neuropsychopharmacology, 2016 Introduction Major depressive disorder (MDD) is a highly prevalent and disabling illness affecting greater than 350 million people worldwide (Kessler et al., 2006).”
BackgroundKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Cognitive impairment in euthymic major depressive disorder: a meta-analysis
Bora, E., Harrison, B. J., Yücel, M., & Pantelis, C. (2013) · Psychological Medicine · doi:10.1017/s0033291712002085 · Cited by 551 · cited 18×
“Due to the known persistence of cognitive dysfunction during remission (Bora et al., 2013) and demonstrated small positive effect of antidepressants on delayed recall and psychomotor speed, the investigation of other cognitively enhancing agents to be used adjunctively to current antidepressants…”
BackgroundInfluentialCognitive impairment in major depression
Marazziti, D., Consoli, G., Picchetti, M., Carlini, M., & Faravelli, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.046 · Cited by 448
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 4×
“Of these studies, one study (Katona et al., 2012) evaluated two agents in parallel compared to placebo, providing a total of five Ta b le 1 .”
BackgroundMethodInfluentialMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Self-citationThe role of cognitive impairment in general functioning in major depression
Baune, B. T., Miller, R., McAfoose, J., Johnson, M., Quirk, F., & Mitchell, D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2008.12.001 · Cited by 378 · cited 18×
“Cognitive dysfunction associated with MDD is a key feature sub-serving the functional impairment associated with MDD (Baune et al., 2010).”
BackgroundInfluentialRaskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.6.900 · Cited by 336
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Bondareff, W., Alpert, M., Friedhoff, A. J., Richter, E. M., Clary, C. M., & Batzar, E. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.729 · Cited by 202
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181 · cited 19×
“(2014) conducted a systematic review on the cognitive effects of pharmacotherapy in MDD, in which they calculated the effect size for all studies reviewed; however, they did not meta-analytically quantify pooled effect sizes of the cognitive effects of antidepressants.”
BackgroundInfluentialSelf-citationA Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163
Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00008 · Cited by 152 · cited 1×
“While studies using TCAs were included, trials assessing the effects of tianeptine were excluded, as the primary mechanism of action of tianeptine is now believed to be via glutamate modulation (Nickel et al., 2003).”
Exercise Fails to Improve Neurocognition in Depressed Middle-Aged and Older Adults
Hoffman, B. M., Blumenthal, J. A., Babyak, M. A., Smith, P. J., Rogers, S. D., Doraiswamy, P. M., & Sherwood, A. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31816b877c · Cited by 123
Baune, B. T., & Renger, L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.013 · Cited by 115 · cited 2×
“Therefore, the results of this pooled effect size may be invalid; however, cognitive dysfunction secondary to TCA use has long been suggested secondary to the anti-cholinergic effects of TCAs (Baune and Renger, 2014; Bortolato et al., 2014; Keefe et al., 2014).”
BackgroundLevkovitz, Y., Caftori, R., Avital, A., & Richter-Levin, G. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00780-8 · Cited by 112
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112 · cited 2×
“Pooled Effect Sizes for Placebo-Controlled Trials Effect on Psychomotor Speed (DSST or Combined Speed) In total, nine placebo-controlled studies evaluated psychomotor speed using DSST or a combined speed measure (Georgotas et al., 1989; Ferguson et al., 2003; Raskin et al., 2007; Hoffman et al., 2008; Culang et al., 2…”
BackgroundMethodCognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08609 · Cited by 107 · cited 3×
“Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed.”
BackgroundMethodChange in Cognitive Functioning Following Acute Antidepressant Treatment in Late-Life Depression
Culang, M. E., Sneed, J. R., Keilp, J. G., Rutherford, B. R., Pelton, G. H., Devanand, D. P., & Roose, S. P. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181b4bf4a · Cited by 94
Comparative Efficacy of Sertraline vs. Fluoxetine in Patients Age 70 or Over With Major Depression
Finkel, S. I., Richter, E. M., Clary, C. M., & Batzar, E. D. (1999) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199908000-00006 · Cited by 76
Acute and Long-term Treatment of Late-Life Major Depressive Disorder: Duloxetine Versus Placebo
Robinson, M. J., Oakes, T. M. M., Raskin, J., Liu, P., Shoemaker, S., & Nelson, J. C. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.019 · Cited by 71
Gorlyn, M., Keilp, J., Burke, A., Oquendo, M., Mann, J. J., & Grunebaum, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.004 · Cited by 70 · cited 8×
“No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs.”
BackgroundInfluentialSoczynska, J. K., Ravindran, L. N., Styra, R., McIntyre, R. S., Cyriac, A., Manierka, M. S., & Kennedy, S. H. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.06.053 · Cited by 60
Self-citationCulang‐Reinlieb, M. E., Sneed, J. R., Keilp, J. G., & Roose, S. P. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2783 · Cited by 37
Georgotas, A., McCue, R. E., Reisberg, B., Ferris, S. H., Nagachandran, N., Chang, I., & Mir, P. (1989) · International Psychogeriatrics · doi:10.1017/s1041610289000141 · Cited by 34
Trick, L., Stanley, N., Rigney, U., & Hindmarch, I. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042622 · Cited by 34
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“In a metaanalysis (17 studies, N 1⁄4 3653) reviewing the cognitive effects of antidepressants based on neuropsychological tests, vortioxetine had the largest effects on processing speed, executive control, and cognitive control, while duloxetine had the largest effects on delayed recall.(17) The quality of these data…”
BackgroundSelf-citationMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Cognitive function following a major depressive episode: a systematic review and meta-analysis
Semkovska, M., Quinlivan, L., O'Grady, T., Johnson, R., Collins, A., O'Connor, J., Knittle, H., Ahern, E., & Gload, T. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30291-3 · Cited by 631
Metadata
- Authors
- Rosenblat, J. D., Kakar, R., & McIntyre, R. S.
- Affiliations
- Western University (CA)
- Corresponding author
- McIntyre, Roger S
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-25
- Volume
- 19
- Issue
- 2
- Pages
- pyv082
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772818
- OpenAlex
- W2212064423
- Semantic Scholar
- af52beccf94ac5808c5f0857633e857371da9c0d
- Cited by
- 315
- References
- 32
- Citations by year
- 2026: 8 · 2025: 27 · 2024: 43 · 2023: 34 · 2022: 28 · 2021: 32 · 2020: 23 · 2019: 35 · 2018: 27 · 2017: 27 · 2016: 27 · 2015: 3
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- major depressive disorder, antidepressants, cognitive impairment, psychomotor speed, delayed recall, executive function, cognitive control, vortioxetine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants
- MeSH terms
- Antidepressive Agents, Cognition, Cognition Disorders, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.